Ascorbic Acid
Active ingredient · 3 therapeutic classes
Sold as Diatrol · Vitavera · Folartex · Davimet-M · Multitol-M
- Drug class
- Ascorbic Acid (Vitamin C), Plain
- Availability
- Prescription and OTC
- Routes
- Oral, Intravenous, Topical, Intramuscular
- Markets covered
- 3
- Products on record
- 68
- FDA reports (12 mo)
- 1,099
Overview
Ascorbic Acid is an active pharmaceutical ingredient in the Ascorbic Acid (Vitamin C), Plain group (A11GA). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 37 | May 19, 2026 |
| US United States | FDA | 24 | January 27, 2027 |
| CA Canada | Health Canada | 7 | April 29, 2026 |
GBUnited Kingdom· MHRA
37 products
Uses
The prevention and treatment of scurvy, or other conditions requiring vitamin C supplementation, where the deficiency is acute or oral administration is difficult.
How to take
USUnited States· FDA
24 products
Uses
INDICATIONS:
PNV-DHA is a multivitamin/multimineral nutritional supplement indicated for use in the dietary management of patients with nutritional deficiencies or are in need of nutritional supplementation.
How to take
CACanada· Health Canada
7 products
7 products on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [3].
Drug interactions
Known interactions involving Ascorbic Acid. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL351040006 · revised December 13, 2024
- [2]FDA DailyMed · 038fe2e7-dc16-48… · revised January 15, 2024 [PDF]
- [3]Health Canada (DPD) · 00780634 · revised March 22, 2025
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.